Comparative efficacy of tarlatamab and second-line therapies in extensive-stage small cell lung cancer: A network meta-analysis
{{output}}
Introduction: In the phase 3 DeLLphi-304 trial, tarlatamab demonstrated significant clinical benefit over second-line (2L) standard-of-care (SOC) chemotherapy options (topotecan, lurbinectedin, amrubicin) in patients with previou... ...
